Last updated: September 2, 2026
Executive summary: Remdesivir, marketed by Gilead Sciences as Veklury, moved from emergency COVID-19 supply to a declining but durable hospital and outpatient antiviral franchise. Global sales peaked at about $5.6 billion in 2021, fell to about $3.9 billion in 2022 and $2.2 billion in 2023 as COVID-19 hospitalizations and testing declined.[1-3] The product remains commercially relevant because it is an FDA-approved treatment for hospitalized and high-risk nonhospitalized patients, has broad geographic availability, and retains intellectual-property protection into the mid-2030s in key markets. Its main risks are demand erosion, oral antiviral competition, reimbursement pressure, and eventual generic entry rather than biosimilar substitution.
Remdesivir Market Dynamics, Financial Trajectory, Patents, Competition, and Generic Entry Risk
Remdesivir is a nucleotide analog antiviral developed by Gilead Sciences and sold in the United States as Veklury. Its commercial profile is unusual: the drug generated multibillion-dollar revenue during the acute COVID-19 pandemic, then entered a long-tail market tied to severe disease, immunocompromised patients, high-risk outpatients, and hospital treatment protocols.
How has remdesivir revenue changed since launch?
Remdesivir revenue peaked in 2021 and has declined each year as COVID-19 moved from pandemic emergency to endemic respiratory disease.
| Fiscal year |
Veklury product sales |
Approximate year-over-year change |
Market context |
| 2020 |
$2.8 billion |
Not comparable |
Launch year; emergency use and hospitalized COVID-19 demand |
| 2021 |
$5.6 billion |
About 98% increase |
Peak hospitalization and government procurement |
| 2022 |
$3.9 billion |
About 30% decline |
Lower hospital volume and reduced pandemic purchasing |
| 2023 |
$2.2 billion |
About 45% decline |
Endemic market, lower COVID-19 severity and utilization |
Sources: Gilead Sciences annual reports and Form 10-K filings.[1-3]
The 2021 peak was driven by inpatient use, government purchasing, and limited early treatment alternatives. Revenue declined as vaccination, prior infection, improved clinical management, and oral antiviral access reduced hospital admissions. Veklury still produced more than $2 billion in 2023, indicating that the product retained a material commercial base after the emergency phase.
Gilead does not report Veklury as a separate operating segment. Product sales are disclosed within the company’s HIV, oncology, liver, and inflammation portfolio reporting, which makes Veklury revenue easier to track than profitability, regional margin, or patient-level utilization.
What are the main market drivers for Veklury?
The commercial market is determined by treatment setting, patient risk, hospital protocols, and COVID-19 epidemiology.
Hospital use remains the core demand source
Remdesivir was initially used primarily in hospitalized patients requiring supplemental oxygen. The FDA approved Veklury in October 2020 for adults and pediatric patients at least 28 days old and weighing at least 3 kilograms who are hospitalized with COVID-19.[4]
Its clinical and commercial position is strongest in:
- Hospitalized patients with moderate or severe COVID-19.
- Patients at high risk of progression who require intravenous therapy.
- Immunocompromised patients with prolonged or recurrent infection.
- Patients for whom an oral antiviral is unsuitable because of drug interactions, renal considerations, swallowing limitations, or delayed presentation.
The need for intravenous administration limits use compared with oral therapies. It requires infusion capacity, pharmacy preparation, and healthcare contact. Those factors support hospital utilization but weaken outpatient adoption.
Outpatient use expanded the addressable market
The FDA expanded Veklury’s indication in January 2022 to include nonhospitalized adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death.[5] The regimen is administered intravenously for three consecutive days.
That expansion created a new commercial channel through outpatient infusion centers, emergency departments, physician practices, and hospital-affiliated clinics. The opportunity is smaller than the original inpatient market because a three-day infusion is operationally more difficult than a five-day oral course.
Seasonality and variant sensitivity affect demand
Revenue is linked to infection waves, hospitalization rates, and the share of infected patients who are medically eligible for antiviral treatment. The product does not depend on a single viral variant in the same way as variant-specific monoclonal antibodies. Remdesivir targets viral RNA polymerase, which gives it a more stable position across SARS-CoV-2 variant cycles.
Its market remains exposed to:
- Lower hospitalization rates.
- Reduced testing and diagnosis.
- Patient reluctance to seek infusion treatment.
- Hospital budget controls.
- Shifts from inpatient to outpatient care.
- Changes in treatment guidelines and payer coverage.
How does remdesivir compare with Paxlovid and Lagevrio?
Remdesivir competes mainly with oral antiviral treatment and supportive care, not only with other intravenous antivirals.
| Product |
Active ingredient |
Route |
Principal commercial advantage |
Principal limitation |
| Veklury |
Remdesivir |
Intravenous infusion |
FDA-approved inpatient and high-risk outpatient use; limited variant-specific vulnerability |
Requires infusion over multiple days |
| Paxlovid |
Nirmatrelvir plus ritonavir |
Oral |
Convenient five-day oral treatment and strong outpatient positioning |
Significant drug-drug interaction burden; renal and hepatic restrictions |
| Lagevrio |
Molnupiravir |
Oral |
Oral administration and fewer logistical barriers |
Lower clinical efficacy and restrictions in some populations |
| Monoclonal antibodies |
Various |
Intravenous or subcutaneous |
Previously useful for targeted neutralization |
Many products lost authorization as variants changed |
Paxlovid is the principal commercial competitor in high-risk outpatient treatment. Its oral route gives it a substantial convenience advantage. Remdesivir retains a role when Paxlovid is contraindicated, clinically unsuitable, unavailable, or considered less appropriate because of interactions.
Molnupiravir competes on access and ease of use but has a weaker efficacy profile. The FDA limited Lagevrio’s use to adults with few alternative treatment options or when alternatives are not clinically appropriate.[6]
What is the FDA regulatory status of remdesivir?
Veklury has full FDA approval, not merely emergency authorization.
| Milestone |
Date |
Regulatory significance |
| FDA Emergency Use Authorization |
May 2020 |
Authorized remdesivir for certain hospitalized COVID-19 patients |
| Initial FDA approval |
October 2020 |
Approved Veklury for adults and certain pediatric patients hospitalized with COVID-19 |
| Pediatric expansion |
2022 |
Broadened use to younger and lower-weight patients |
| Outpatient approval |
January 2022 |
Approved a three-day intravenous course for high-risk nonhospitalized patients |
| Current positioning |
2024 |
FDA-approved COVID-19 antiviral for defined inpatient and outpatient populations |
Sources: FDA prescribing information and FDA announcements.[4-6]
The full approval supports guideline inclusion, hospital formulary access, and payer reimbursement. It also differentiates Veklury from products that relied primarily on emergency authorization.
What patents protect remdesivir and Veklury?
Remdesivir is protected by composition-of-matter, prodrug, formulation, manufacturing, and method-of-use patent families. The central U.S. composition patent family includes U.S. Patent No. 10,251,904, which covers phosphoramidate prodrugs associated with remdesivir and related compounds.[7]
Patent categories
| Protection category |
Commercial relevance |
| Active compound and prodrug claims |
Protect remdesivir itself and structurally related compounds |
| Pharmaceutical composition claims |
Cover injectable formulations, excipients, and dosage forms |
| Manufacturing and synthesis claims |
Raise process-development and freedom-to-operate barriers |
| Method-of-use claims |
Cover treatment of coronavirus infections and selected patient populations |
| International family members |
Extend protection across major pharmaceutical markets |
The primary U.S. patent estate extends into the mid-2030s based on publicly available patent-family and Orange Book data. Exact enforceable dates may vary by patent, patent-term adjustment, pediatric exclusivity, terminal disclaimers, and jurisdiction.[7-9]
Veklury’s practical exclusivity is therefore longer than its regulatory exclusivity alone. The commercial barrier depends on which claims a generic applicant must challenge and whether the relevant patents are listed for the specific approved product.
What is the Orange Book status of Veklury?
Veklury is an FDA-approved small-molecule drug listed in FDA product and patent databases. It is not a biologic and does not follow the biosimilar pathway.[4,8]
The Orange Book is relevant because it identifies patents submitted by the sponsor for approved drug products and establishes the patent-certification framework for abbreviated new drug applications. A generic applicant seeking approval before listed patent expiry may submit:
- Paragraph I certification, stating that no patent information is listed.
- Paragraph II certification, stating that the patent has expired.
- Paragraph III certification, accepting approval after patent expiry.
- Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.
The commercial importance of any Paragraph IV filing depends on the scope and remaining term of the listed patents, the timing of FDA filing, and whether Gilead initiates litigation within the statutory period.
Are there Paragraph IV challenges or remdesivir patent lawsuits?
A Paragraph IV challenge would be the standard U.S. route for an abbreviated generic application seeking approval before expiration of relevant Veklury patents. A public patent challenge could target compound claims, formulation claims, or treatment-method claims.
The principal litigation risks are:
- Validity challenges. A generic applicant could argue lack of novelty, obviousness, inadequate written description, or enablement.
- Noninfringement arguments. A manufacturer could develop a process or formulation outside the asserted claims.
- Claim fragmentation. Different patents may protect different aspects of the product, allowing a generic to challenge one layer while avoiding another.
- Regulatory carve-outs. A generic could seek approval for uses that omit patented indications, subject to FDA labeling rules.
- Settlement timing. A settlement could establish a launch date before the latest patent expiry without eliminating patent protection.
No biosimilar litigation framework applies. Any U.S. challenge would be a generic-drug patent dispute under the Hatch-Waxman Act rather than a BPCIA biosimilar dispute.
When does remdesivir lose exclusivity?
Remdesivir does not have one universal loss-of-exclusivity date. The relevant date depends on the patent, country, product presentation, and approved indication.
U.S. exclusivity timing
The most important U.S. patent protection reaches into the mid-2030s. That creates a long runway before unrestricted generic substitution becomes likely. Regulatory exclusivity from the original approval is shorter and has already expired or materially diminished; the commercial barrier now depends primarily on patents, manufacturing capability, and market economics.[4,7-9]
Potential U.S. entry scenarios include:
| Scenario |
Likely timing logic |
Commercial effect |
| No successful early challenge |
After the last enforceable key patent |
Delayed broad generic entry |
| Successful Paragraph IV challenge |
Before patent expiry |
Rapid price and share erosion |
| At-risk launch after litigation |
Before final judgment or settlement |
High legal exposure for the generic |
| Carved-out indication |
Before full patent expiry |
Limited entry by selected use |
| Post-expiry launch |
After relevant patents expire |
Standard injectable generic competition |
The product’s intravenous formulation creates a higher manufacturing threshold than an ordinary oral tablet. That may reduce the number of immediate generic competitors even after legal entry becomes possible.
What licensing deals affected remdesivir access?
In October 2020, Gilead entered voluntary licensing arrangements with the Medicines Patent Pool to expand access in 127 low- and middle-income countries.[10] The agreements authorized multiple manufacturers to produce and supply generic remdesivir for specified markets.
The access structure reduced reliance on a single global supplier and allowed local or regional production. It also created a two-tier commercial environment:
- High-income markets generally remained supplied through Gilead’s branded channel or commercial partners.
- Licensed lower-income markets could receive generic or locally manufactured remdesivir under defined territorial and regulatory terms.
The licenses did not eliminate Gilead’s global patent estate. They established contractual access within specified countries and under negotiated conditions.
How strong is the remdesivir patent estate?
The patent estate is commercially meaningful but not immune to challenge.
Strengths
- A composition-of-matter platform generally provides stronger protection than a narrow method-of-use patent.
- The product has full FDA approval and an established formulation.
- Patent protection extends well beyond the pandemic launch period.
- Injectable manufacturing and quality requirements create barriers beyond patent law.
- Gilead controls the branded product, regulatory dossier, and clinical-development history.
Weaknesses
- Remdesivir’s discovery and development history may provide prior-art targets for validity challenges.
- Multiple patent families can create claim overlap and prosecution-history issues.
- Method-of-use patents are narrower than composition patents.
- A generic may design around particular formulation or process claims.
- Declining demand reduces the economic value of litigation and may encourage selective generic entry.
Overall, the estate is stronger against immediate unrestricted substitution than against targeted challenges to individual patents or selected indications.
What manufacturing and intellectual-property barriers affect generic entry?
Remdesivir is administered intravenously and requires sterile drug-product manufacturing. A generic entrant must demonstrate pharmaceutical equivalence, bioequivalence or an appropriate alternative standard, sterility, stability, container compatibility, and reliable supply.
The main barriers are:
- Complex synthesis of the nucleotide phosphoramidate prodrug.
- Control of stereochemistry and impurities.
- Sterile injectable production.
- Scale-up and batch consistency.
- Drug-substance and drug-product validation.
- Clinical-use labeling restrictions.
- Hospital procurement contracts.
- Low and uncertain post-pandemic demand.
- Exposure to multiple patent families.
A generic manufacturer may obtain legal clearance yet still struggle to justify the capital required for an injectable product with declining annual sales. This makes the commercial launch threshold higher than the patent expiry date alone suggests.
Which companies are challenging or competing with Gilead?
The competitive field includes Pfizer, Merck, generic manufacturers, and hospital-based treatment providers.
- Pfizer competes through Paxlovid, the leading oral antiviral alternative for high-risk outpatients.
- Merck competes through Lagevrio, primarily where other treatment options are unsuitable.
- Generic manufacturers compete in licensed low- and middle-income markets and may pursue future U.S. abbreviated approvals.
- Manufacturers of supportive-care products indirectly compete by reducing the need for antiviral treatment through earlier diagnosis, vaccination, and improved hospital protocols.
There is no biosimilar competitor because remdesivir is a chemically synthesized small molecule. The relevant future competitors are authorized generics and conventional ANDA applicants.
What is the revenue exposure for Gilead?
Veklury remains a material but declining contributor to Gilead’s consolidated revenue. Its strategic importance is lower than its 2021 sales peak because Gilead’s HIV portfolio, including Biktarvy and long-acting therapies, provides the company’s primary recurring revenue base.[1-3]
The financial profile has three phases:
- Pandemic monetization, 2020-2021. Rapid uptake generated approximately $8.4 billion across the first two commercial years.
- Normalization, 2022-2023. Sales fell as hospitalization and government procurement declined.
- Endemic tail, 2024 onward. Revenue depends on high-risk treatment demand, seasonal waves, outpatient infusion access, and guideline persistence.
Veklury’s gross-margin contribution may remain attractive because the core product is established, but declining volume can increase manufacturing and inventory inefficiency. Government purchasing also creates working-capital and forecasting risk.
What generic launch risks exist for remdesivir?
The most plausible generic-entry pattern is gradual rather than an immediate flood of competitors.
Early-entry risk
A successful Paragraph IV challenge could create an early launch opportunity. The first approved generic could capture hospitals with aggressive formulary substitution, particularly if Gilead’s price premium remains high.
Post-expiry erosion
After the last meaningful patent barrier expires, injectable generic competition could reduce price and market share. The pace may be slower than for oral products because of sterile manufacturing constraints and limited demand.
Geographic fragmentation
Generic access may begin in countries covered by voluntary licenses or where patent protection is weaker. U.S., European, and emerging-market entry dates may differ materially.
Commercial erosion before patent expiry
Gilead can lose revenue before generic entry through:
- Reduced COVID-19 incidence.
- Greater use of Paxlovid.
- Lower hospitalization rates.
- Hospital price negotiations.
- Payer restrictions on infusion treatment.
- Clinical preference for oral or shorter-treatment alternatives.
Key Takeaways
- Veklury revenue peaked at about $5.6 billion in 2021 and declined to about $2.2 billion in 2023.
- The product remains FDA-approved for hospitalized patients and high-risk nonhospitalized patients.
- Paxlovid is the principal outpatient competitor because of its oral route.
- Remdesivir is a small molecule, so future competition will come from generics, not biosimilars.
- Key U.S. patent protection extends into the mid-2030s based on public patent and Orange Book data.
- Voluntary licenses expanded access in 127 low- and middle-income countries.
- The strongest barriers to entry are the patent estate, sterile injectable manufacturing, and uncertain post-pandemic demand.
- Financial risk is driven more by volume erosion and competitive substitution than by immediate patent expiry.
FAQs About Remdesivir Patent and Market Risk
Can remdesivir be substituted automatically at U.S. pharmacies?
No. Veklury is an intravenous administered product, so substitution generally occurs through hospital or provider procurement rather than ordinary retail-pharmacy interchangeability.
Does Paxlovid make remdesivir commercially obsolete?
No. Paxlovid has a convenience advantage, but remdesivir remains relevant for patients with contraindications, drug interactions, treatment failure, or a need for intravenous therapy.
Does remdesivir have pediatric exclusivity?
FDA approval covers defined pediatric populations, but pediatric use does not mean that the entire product receives a new period of pediatric exclusivity. The effect depends on the applicable FDA exclusivity record and completed statutory studies.[4,8]
Can a generic manufacturer launch remdesivir without copying Gilead’s manufacturing process?
Yes, if it develops a noninfringing process and satisfies FDA quality and approval requirements. Process patents and manufacturing know-how can still create substantial barriers.
Why did remdesivir sales fall even though COVID-19 treatment remained available?
Sales fell because the number of severe cases and hospitalizations declined, vaccination and prior immunity reduced disease burden, oral treatments captured outpatient demand, and emergency procurement programs contracted.[1-3]
References
-
Gilead Sciences, Inc. (2021). 2020 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2022). 2021 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2024). 2023 annual report. Gilead Sciences.
-
U.S. Food and Drug Administration. (2024). Veklury (remdesivir) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022, January 21). FDA approves Veklury for pediatric patients and expands outpatient treatment indication. FDA.
-
U.S. Food and Drug Administration. (2022). FDA announces limitations on authorized use of Lagevrio. FDA.
-
U.S. Patent No. 10,251,904. (2019). Phosphoramidate prodrugs of nucleoside analogues. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. USPTO.
-
Medicines Patent Pool. (2020, October 12). Medicines Patent Pool and Gilead announce licensing agreements for remdesivir. MPP.
